An Open-Label, Dose-Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Six Different Strengths in Healthy Male Volunteers.

Trial Profile

An Open-Label, Dose-Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Six Different Strengths in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs PR 15 (Primary)
  • Indications Atherosclerosis; Thrombosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors advanceCor
  • Most Recent Events

    • 18 Oct 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 15 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top